Clinical Trial Update: Clinical Gene Therapy Protocol for the Treatment of Retinal Dystrophy Caused by Defects in RPE65 [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update describes a Phase 1/Phase 2 gene therapy protocol for retinal dystrophy due to RPE65 defects in Leber congenital amaurosis. The trial…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leber Congenital Amaurosis

Snippet

Sponsor: Nantes University Hospital | Conditions: Leber Congenital Amaurosis | Phase 1, Phase 2 | Status: COMPLETED